Medicare Contractor Changing from Noridian or WPS to National Government Services:

Minnesota and Wisconsin are moving to the new J6 Regional Medicare Contractor. Part A Services will convert effective August 10th and Part B Services will convert effective September 10th. Part of the conversion will include Local Coverage Policies that impact laboratory testing. A summary of the new Coverage Policies are detailed below. These policies are in conjunction with the National Coverage Policies (NCD) that remain in effect. HML Policy Changes will go into effect on August 10, 2013!

**LCD for Galectin-3 (L32977)**

Review of the literature suggests that at some point this assay may be found useful in the management of congestive heart failure. Presently, National Government Services considers this assay for CHF patients and similar assays related to the elaboration of galectin-3 protein to be of an uncertain role in the clinical management of patients. **Consequently, it is considered not covered for all indications.**

**CPT/HCPCS Codes**

82777 GALECTIN-3

**LCD for Combined Ovarian Cancer Biomarker Tests (L32589)**

At the present time, National Government Services does not find either the OVA-1 or the ROMA™ test to be of proven efficacy in the diagnosis or treatment of ovarian cancer. National Government Services will only allow coverage of CA-125 as allowed by the national coverage decision.

**CPT/HCPCS Codes**

84999 UNLISTED CHEMISTRY PROCEDURE

**LCD for B-type Natriuretic Peptide (BNP) Testing (L26375)**

BNP measurements must be analyzed in conjunction with standard diagnostic tests, medical history and clinical findings. The efficacy of BNP measurement as a stand-alone test has not yet been established. Clinicians should be aware that certain conditions such as ischemia, infarction and renal insufficiency, may cause elevation of circulating BNP concentration and require alterations of the interpretation of BNP results.

Additional investigation is required to further define the diagnostic value of plasma BNP in monitoring the efficiency of treatment for CHF and in tailoring the therapy for heart failure. **Therefore, BNP measurements for monitoring and management of CHF are not a covered service.**

Although a correlation between serum BNP levels and the clinical severity of HF has been shown in broad populations, “it cannot be assumed that BNP levels can be used effectively as targets for adjustment of therapy in individual patients. [T]he BNP measurement has not been clearly shown to supplement careful clinical
CPT/HCPCS Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>83880</td>
<td>NATRIURETIC PEPTIDE</td>
</tr>
</tbody>
</table>

ICD-9-CM codes that support medical necessity when billed in either an office or outpatient setting.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>402.01</td>
<td>MALIGNANT HYPERTENSIVE HEART DISEASE WITH HEART FAILURE</td>
</tr>
<tr>
<td>402.11</td>
<td>BENIGN HYPERTENSIVE HEART DISEASE WITH HEART FAILURE</td>
</tr>
<tr>
<td>402.91</td>
<td>UNSPECIFIED HYPERTENSIVE HEART DISEASE WITH HEART FAILURE</td>
</tr>
<tr>
<td>404.01</td>
<td>HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED</td>
</tr>
<tr>
<td>404.03</td>
<td>HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE</td>
</tr>
<tr>
<td>404.11</td>
<td>HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED</td>
</tr>
<tr>
<td>404.13</td>
<td>HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE</td>
</tr>
<tr>
<td>404.91</td>
<td>HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED</td>
</tr>
<tr>
<td>404.93</td>
<td>HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE</td>
</tr>
<tr>
<td>428.0</td>
<td>CONGESTIVE HEART FAILURE UNSPECIFIED</td>
</tr>
<tr>
<td>428.1</td>
<td>LEFT HEART FAILURE</td>
</tr>
<tr>
<td>428.20</td>
<td>UNSPECIFIED SYSTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.21</td>
<td>ACUTE SYSTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.22</td>
<td>CHRONIC SYSTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.23</td>
<td>ACUTE ON CHRONIC SYSTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.30</td>
<td>UNSPECIFIED DIASTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.31</td>
<td>ACUTE DIASTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.32</td>
<td>CHRONIC DIASTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.33</td>
<td>ACUTE ON CHRONIC DIASTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.40</td>
<td>UNSPECIFIED COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.41</td>
<td>ACUTE COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.42</td>
<td>CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.43</td>
<td>ACUTE ON CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE</td>
</tr>
<tr>
<td>428.9</td>
<td>HEART FAILURE UNSPECIFIED</td>
</tr>
</tbody>
</table>
OBSTRUCTIVE CHRONIC BRONCHITIS WITH (ACUTE) EXACERBATION
OBSTRUCTIVE CHRONIC BRONCHITIS WITH ACUTE BRONCHITIS
CHRONIC OBSTRUCTIVE ASThma WITH (ACUTE) EXACERBATION
ASThma UNSPECIFIED WITH (ACUTE) EXACERBATION
ACUTE BRONCHOSPASM
RESPIRATORY ABNORMALITY UNSPECIFIED
ORTHOPNEA
SHORTNESS OF BREATH
TACHYPNEA
WHEEZING
RESPIRATORY ABNORMALITY OTHER

**LCD for Vitamin D Assay Testing (L29510)**

For Medicare beneficiaries, screening tests are governed by statute. **Vitamin D testing may not be used for routine screening.** Once a beneficiary has been shown to be vitamin D deficient, further testing is medically necessary only to ensure adequate replacement has been accomplished. Thereafter, annual testing may be appropriate depending upon the indication and other mitigating factors.

**CPT/HCPCS Codes**

82306 VITAMIN D; 25 HYDROXY, INCLUDES FRACTION(S), IF PERFORMED

**ICD-9 Codes that Support Medical Necessity**

252.00 HYPERPARATHYROIDISM, UNSPECIFIED
252.01 PRIMARY HYPERPARATHYROIDISM
252.02 SECONDARY HYPERPARATHYROIDISM, NON-RENAL
252.08 OTHER HYPERPARATHYROIDISM
252.1 HYPOPARATHYROIDISM
268.0 RICKETS ACTIVE
268.2 OSTEOMALACIA UNSPECIFIED
268.9 UNSPECIFIED VITAMIN D DEFICIENCY
275.3 DISORDERS OF PHOSPHORUS METABOLISM
275.41 HYPOCALCEMIA
275.42 HYPERCALCEMIA
585.3 CHRONIC KIDNEY DISEASE, STAGE III (MODERATE)
585.4 CHRONIC KIDNEY DISEASE, STAGE IV (SEVERE)
585.5 CHRONIC KIDNEY DISEASE, STAGE V
A qualitative drug screen is not medically reasonable or necessary to screen for the same drug with both a blood and a urine specimen simultaneously.

Medicare regards drug screening for medico-legal purposes (e.g., court-ordered drug screening) or for employment purposes (e.g., as a pre-requisite for employment or as a requirement for continuation of employment) as not medically necessary.

**CPT/HCPCS Codes**

- **80102** DRUG CONFIRMATION, EACH PROCEDURE
- **G0431** DRUG SCREEN, QUALITATIVE; MULTIPLE DRUG CLASSES BY HIGH COMPLEXITY TEST METHOD (E.G., IMMUNOASSAY, ENZYME ASSAY), PER PATIENT ENCOUNTER
- **G0434** DRUG SCREEN, OTHER THAN CHROMATOGRAPHIC; ANY NUMBER OF DRUG CLASSES, BY CLIA WAIVED TEST OR MODERATE COMPLEXITY TEST, PER PATIENT ENCOUNTER

**ICD-9 Codes that Support Medical Necessity**

- **276.2** ACIDOSIS
- **304.00** OPIOID TYPE DEPENDENCE UNSPECIFIED USE
- **304.01** OPIOID TYPE DEPENDENCE CONTINUOUS USE
- **304.02** OPIOID TYPE DEPENDENCE EPISODIC USE
- **304.03** OPIOID TYPE DEPENDENCE IN REMISSION
- **304.10** SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNSPECIFIED
- **304.11** SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, CONTINUOUS
- **304.12** SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, EPISODIC
- **304.13** SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION
- **304.20** COCAINE DEPENDENCE UNSPECIFIED USE
- **304.21** COCAINE DEPENDENCE CONTINUOUS USE
- **304.22** COCAINE DEPENDENCE EPISODIC USE
- **304.23** COCAINE DEPENDENCE IN REMISSION
- **304.30** CANNABIS DEPENDENCE UNSPECIFIED USE
- **304.31** CANNABIS DEPENDENCE CONTINUOUS USE
- **304.32** CANNABIS DEPENDENCE EPISODIC USE
- **304.33** CANNABIS DEPENDENCE IN REMISSION
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>304.40</td>
<td>AMPHETAMINE AND OTHER PSYCHOSTIMULANT DEPENDENCE UNSPECIFIED USE</td>
</tr>
<tr>
<td>304.41</td>
<td>AMPHETAMINE AND OTHER PSYCHOSTIMULANT DEPENDENCE CONTINUOUS USE</td>
</tr>
<tr>
<td>304.42</td>
<td>AMPHETAMINE AND OTHER PSYCHOSTIMULANT DEPENDENCE EPISODIC USE</td>
</tr>
<tr>
<td>304.43</td>
<td>AMPHETAMINE AND OTHER PSYCHOSTIMULANT DEPENDENCE IN REMISSION</td>
</tr>
<tr>
<td>304.50</td>
<td>HALLUCINOGEN DEPENDENCE UNSPECIFIED USE</td>
</tr>
<tr>
<td>304.51</td>
<td>HALLUCINOGEN DEPENDENCE CONTINUOUS USE</td>
</tr>
<tr>
<td>304.52</td>
<td>HALLUCINOGEN DEPENDENCE EPISODIC USE</td>
</tr>
<tr>
<td>304.53</td>
<td>HALLUCINOGEN DEPENDENCE IN REMISSION</td>
</tr>
<tr>
<td>304.60</td>
<td>OTHER SPECIFIED DRUG DEPENDENCE UNSPECIFIED USE</td>
</tr>
<tr>
<td>304.61</td>
<td>OTHER SPECIFIED DRUG DEPENDENCE CONTINUOUS USE</td>
</tr>
<tr>
<td>304.62</td>
<td>OTHER SPECIFIED DRUG DEPENDENCE EPISODIC USE</td>
</tr>
<tr>
<td>304.63</td>
<td>OTHER SPECIFIED DRUG DEPENDENCE IN REMISSION</td>
</tr>
<tr>
<td>304.70</td>
<td>COMBINATIONS OF OPIOID TYPE DRUG WITH ANY OTHER DRUG DEPENDENCE UNSPECIFIED USE</td>
</tr>
<tr>
<td>304.71</td>
<td>COMBINATIONS OF OPIOID TYPE DRUG WITH ANY OTHER DRUG DEPENDENCE CONTINUOUS USE</td>
</tr>
<tr>
<td>304.72</td>
<td>COMBINATIONS OF OPIOID TYPE DRUG WITH ANY OTHER DRUG DEPENDENCE EPISODIC USE</td>
</tr>
<tr>
<td>304.73</td>
<td>COMBINATIONS OF OPIOID TYPE DRUG WITH ANY OTHER DRUG DEPENDENCE IN REMISSION</td>
</tr>
<tr>
<td>304.80</td>
<td>COMBINATIONS OF DRUG DEPENDENCE EXCLUDING OPIOID TYPE DRUG UNSPECIFIED USE</td>
</tr>
<tr>
<td>304.81</td>
<td>COMBINATIONS OF DRUG DEPENDENCE EXCLUDING OPIOID TYPE DRUG CONTINUOUS USE</td>
</tr>
<tr>
<td>304.82</td>
<td>COMBINATIONS OF DRUG DEPENDENCE EXCLUDING OPIOID TYPE DRUG EPISODIC USE</td>
</tr>
<tr>
<td>304.83</td>
<td>COMBINATIONS OF DRUG DEPENDENCE EXCLUDING OPIOID TYPE DRUG IN REMISSION</td>
</tr>
<tr>
<td>304.90</td>
<td>UNSPECIFIED DRUG DEPENDENCE UNSPECIFIED USE</td>
</tr>
<tr>
<td>304.91</td>
<td>UNSPECIFIED DRUG DEPENDENCE CONTINUOUS USE</td>
</tr>
<tr>
<td>304.92</td>
<td>UNSPECIFIED DRUG DEPENDENCE EPISODIC USE</td>
</tr>
<tr>
<td>304.93</td>
<td>UNSPECIFIED DRUG DEPENDENCE IN REMISSION</td>
</tr>
<tr>
<td>305.00</td>
<td>NONDEPENDENT ALCOHOL ABUSE UNSPECIFIED DRINKING BEHAVIOR</td>
</tr>
<tr>
<td>305.01</td>
<td>NONDEPENDENT ALCOHOL ABUSE CONTINUOUS DRINKING BEHAVIOR</td>
</tr>
<tr>
<td>305.02</td>
<td>NONDEPENDENT ALCOHOL ABUSE EPISODIC DRINKING BEHAVIOR</td>
</tr>
<tr>
<td>305.03</td>
<td>NONDEPENDENT ALCOHOL ABUSE IN REMISSION</td>
</tr>
<tr>
<td>305.20</td>
<td>NONDEPENDENT CANNABIS ABUSE UNSPECIFIED USE</td>
</tr>
<tr>
<td>305.21</td>
<td>NONDEPENDENT CANNABIS ABUSE CONTINUOUS USE</td>
</tr>
<tr>
<td>305.22</td>
<td>NONDEPENDENT CANNABIS ABUSE EPISODIC USE</td>
</tr>
<tr>
<td>305.23</td>
<td>NONDEPENDENT CANNABIS ABUSE IN REMISSION</td>
</tr>
<tr>
<td>305.30</td>
<td>NONDEPENDENT HALLUCINOCGEN ABUSE UNSPECIFIED USE</td>
</tr>
<tr>
<td>305.31</td>
<td>NONDEPENDENT HALLUCINOCGEN ABUSE CONTINUOUS USE</td>
</tr>
<tr>
<td>305.32</td>
<td>NONDEPENDENT HALLUCINOCGEN ABUSE EPISODIC USE</td>
</tr>
<tr>
<td>305.33</td>
<td>NONDEPENDENT HALLUCINOCGEN ABUSE IN REMISSION</td>
</tr>
<tr>
<td>305.40</td>
<td>SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, UNSPECIFIED</td>
</tr>
<tr>
<td>305.41</td>
<td>SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, CONTINUOUS</td>
</tr>
<tr>
<td>305.42</td>
<td>SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, EPISODIC</td>
</tr>
<tr>
<td>305.43</td>
<td>SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, IN REMISSION</td>
</tr>
<tr>
<td>305.50</td>
<td>NONDEPENDENT OPIOID ABUSE UNSPECIFIED USE</td>
</tr>
<tr>
<td>305.51</td>
<td>NONDEPENDENT OPIOID ABUSE CONTINUOUS USE</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------------------</td>
</tr>
<tr>
<td>305.52</td>
<td>NONDEPENDENT OPIOID ABUSE EPISODIC USE</td>
</tr>
<tr>
<td>305.53</td>
<td>NONDEPENDENT OPIOID ABUSE IN REMISSION</td>
</tr>
<tr>
<td>305.60</td>
<td>NONDEPENDENT COCAINE ABUSE UNSPECIFIED USE</td>
</tr>
<tr>
<td>305.61</td>
<td>NONDEPENDENT COCAINE ABUSE CONTINUOUS USE</td>
</tr>
<tr>
<td>305.62</td>
<td>NONDEPENDENT COCAINE ABUSE EPISODIC USE</td>
</tr>
<tr>
<td>305.63</td>
<td>NONDEPENDENT COCAINE ABUSE IN REMISSION</td>
</tr>
<tr>
<td>305.70</td>
<td>NONDEPENDENT AMPHETAMINE OR RELATED ACTING SYMPATHOMIMETIC ABUSE UNSPECIFIED USE</td>
</tr>
<tr>
<td>305.71</td>
<td>NONDEPENDENT AMPHETAMINE OR RELATED ACTING SYMPATHOMIMETIC ABUSE CONTINUOUS USE</td>
</tr>
<tr>
<td>305.72</td>
<td>NONDEPENDENT AMPHETAMINE OR RELATED ACTING SYMPATHOMIMETIC ABUSE EPISODIC USE</td>
</tr>
<tr>
<td>305.73</td>
<td>NONDEPENDENT AMPHETAMINE OR RELATED ACTING SYMPATHOMIMETIC ABUSE IN REMISSION</td>
</tr>
<tr>
<td>305.80</td>
<td>NONDEPENDENT ANTIDEPRESSANT TYPE ABUSE UNSPECIFIED USE</td>
</tr>
<tr>
<td>305.81</td>
<td>NONDEPENDENT ANTIDEPRESSANT TYPE ABUSE CONTINUOUS USE</td>
</tr>
<tr>
<td>305.82</td>
<td>NONDEPENDENT ANTIDEPRESSANT TYPE ABUSE EPISODIC USE</td>
</tr>
<tr>
<td>305.83</td>
<td>NONDEPENDENT ANTIDEPRESSANT TYPE ABUSE EPISODIC USE</td>
</tr>
<tr>
<td>305.90</td>
<td>OTHER MIXED OR UNSPECIFIED DRUG ABUSE UNSPECIFIED USE</td>
</tr>
<tr>
<td>305.91</td>
<td>NONDEPENDENT OTHER MIXED OR UNSPECIFIED DRUG ABUSE CONTINUOUS USE</td>
</tr>
<tr>
<td>305.92</td>
<td>NONDEPENDENT OTHER MIXED OR UNSPECIFIED DRUG ABUSE EPISODIC USE</td>
</tr>
<tr>
<td>305.93</td>
<td>NONDEPENDENT OTHER MIXED OR UNSPECIFIED DRUG ABUSE IN REMISSION</td>
</tr>
<tr>
<td>345.10</td>
<td>GENERALIZED CONVULSIVE EPILEPSY WITHOUT INTRACTABLE EPILEPSY</td>
</tr>
<tr>
<td>345.11</td>
<td>GENERALIZED CONVULSIVE EPILEPSY WITH INTRACTABLE EPILEPSY</td>
</tr>
<tr>
<td>345.3</td>
<td>GRAND MAL STATUS EPILEPTIC</td>
</tr>
<tr>
<td>345.90</td>
<td>EPILEPSY UNSPECIFIED WITHOUT INTRACTABLE EPILEPSY</td>
</tr>
<tr>
<td>345.91</td>
<td>EPILEPSY UNSPECIFIED WITH INTRACTABLE EPILEPSY</td>
</tr>
<tr>
<td>426.10</td>
<td>ATRIOVENTRICULAR BLOCK UNSPECIFIED</td>
</tr>
<tr>
<td>426.11</td>
<td>FIRST DEGREE ATRIOVENTRICULAR BLOCK</td>
</tr>
<tr>
<td>426.12</td>
<td>MOBITZ (TYPE) II ATRIOVENTRICULAR BLOCK</td>
</tr>
<tr>
<td>426.13</td>
<td>OTHER SECOND DEGREE ATRIOVENTRICULAR BLOCK</td>
</tr>
<tr>
<td>426.82</td>
<td>LONG QT SYNDROME</td>
</tr>
<tr>
<td>427.0</td>
<td>PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA</td>
</tr>
<tr>
<td>427.1</td>
<td>PAROXYSMAL VENTRICULAR TACHYCARDIA</td>
</tr>
<tr>
<td>780.01</td>
<td>COMA</td>
</tr>
<tr>
<td>780.09</td>
<td>ALTERATION OF CONSCIOUSNESS OTHER</td>
</tr>
<tr>
<td>780.1</td>
<td>HALLUCINATIONS</td>
</tr>
<tr>
<td>780.39</td>
<td>OTHER CONVULSIONS</td>
</tr>
<tr>
<td>780.97</td>
<td>ALTERED MENTAL STATUS</td>
</tr>
<tr>
<td>963.0</td>
<td>POISONING BY ANTIALLERGIC AND ANTIEMETIC DRUGS</td>
</tr>
<tr>
<td>965.00</td>
<td>POISONING BY OPIUM (ALKALOIDS) UNSPECIFIED</td>
</tr>
<tr>
<td>965.01</td>
<td>POISONING BY HEROIN</td>
</tr>
<tr>
<td>965.02</td>
<td>POISONING BY METHADONE</td>
</tr>
<tr>
<td>965.09</td>
<td>POISONING BY OTHER OPIATES AND RELATED NARCOTICS</td>
</tr>
<tr>
<td>965.1</td>
<td>POISONING BY SALICYLATES</td>
</tr>
<tr>
<td>965.4</td>
<td>POISONING BY AROMATIC ANALGESICS NOT ELSEWHERE CLASSIFIED</td>
</tr>
</tbody>
</table>
965.5  POISONING BY PYRAZOLE DERIVATIVES
965.61 POISONING BY PROPIONIC ACID DERIVATIVES
966.1  POISONING BY HYDANTOIN DERIVATIVES
967.0  POISONING BY BARBITURATES
967.1  POISONING BY CHLORAL HYDRATE GROUP
967.2  POISONING BY PARALDEHYDE
967.3  POISONING BY BROMINE COMPOUNDS
967.4  POISONING BY METHAQUALONE COMPOUNDS
967.5  POISONING BY GLUTETHIMIDE GROUP
967.6  POISONING BY MIXED SEDATIVES NOT ELSEWHERE CLASSIFIED
967.8  POISONING BY OTHER SEDATIVES AND HYPNOTICS
967.9  POISONING BY UNSPECIFIED SEDATIVE OR HYPNOTIC
969.00 POISONING BY ANTIDEPRESSANT, UNSPECIFIED
969.01 POISONING BY MONOAMINE OXIDASE INHIBITORS
969.02 POISONING BY SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS
969.03 POISONING BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS
969.04 POISONING BY TETRACYCLIC ANTIDEPRESSANTS
969.05 POISONING BY TRICYCLIC ANTIDEPRESSANTS
969.09 POISONING BY OTHER ANTIDEPRESSANTS
969.1  POISONING BY PHENOTHIAZINE-BASED TRANQUILIZERS
969.2  POISONING BY BUTYROPHENONE-BASED TRANQUILIZERS
969.3  POISONING BY OTHER ANTIPSYCHOTICS NEUROLEPTICS AND MAJOR TRANQUILIZERS
969.4  POISONING BY BENZODIAZEPINE-BASED TRANQUILIZERS
969.5  POISONING BY OTHER TRANQUILIZERS
969.6  POISONING BY PSYCHODYSLPTEICS (HALLUCINOGENS)
969.70 POISONING BY PSYCHOSTIMULANT, UNSPECIFIED
969.71 POISONING BY CAFFEINE
969.72 POISONING BY AMPHETAMINES
969.73 POISONING BY METHYLPHENIDATE
969.79 POISONING BY OTHER PSYCHOSTIMULANTS
969.8  POISONING BY OTHER SPECIFIED PSYCHOTROPIC AGENTS
969.9  POISONING BY UNSPECIFIED PSYCHOTROPIC AGENT
970.81 POISONING BY COCAINE
970.89 POISONING BY OTHER CENTRAL NERVOUS SYSTEM STIMULANTS
972.1  POISONING BY CARDIOTONIC GLYCOSIDES AND DRUGS OF SIMILAR ACTION
977.9  POISONING BY UNSPECIFIED DRUG OR MEDICINAL SUBSTANCE
V15.81 PERSONAL HISTORY OF NONCOMPLIANCE WITH MEDICAL TREATMENT PRESENTING HAZARDS TO HEALTH
V58.69 LONG-TERM (CURRENT) USE OF OTHER MEDICATIONS
V71.09 OBSERVATION OF OTHER SUSPECTED MENTAL CONDITION

LCD for RAST Type Tests (L28463)
CPT/HCPCS Codes (Note: CPT codes 86001 and 86005 are not covered services)

86001   ALLERGEN SPECIFIC IGG QUANTITATIVE OR SEMIQUANTITATIVE, EACH ALLERGEN
86003   ALLERGEN SPECIFIC IGE; QUANTITATIVE OR SEMIQUANTITATIVE, EACH ALLERGEN
86005   ALLERGEN SPECIFIC IGE; QUALITATIVE, MULTIALLERGEN SCREEN (DIPSTICK, PADDLE, OR DISK)

ICD-9 Codes that Support Medical Necessity - The following ICD-9 Codes apply only to CPT code 86003:

477.0   ALLERGIC RHINITIS DUE TO POLLEN
477.1   ALLERGIC RHINITIS DUE TO FOOD
477.2   ALLERGIC RHINITIS, DUE TO ANIMAL (CAT) (DOG) HAIR AND DANDER
477.8   ALLERGIC RHINITIS DUE TO OTHER ALLERGEN
477.9   ALLERGIC RHINITIS CAUSE UNSPECIFIED
493.00  EXTRINSIC ASTHMA UNSPECIFIED
493.01  EXTRINSIC ASTHMA WITH STATUS ASTHMATICUS
493.02  EXTRINSIC ASTHMA WITH (ACUTE) EXACERBATION
493.82  COUGH VARIANT ASTHMA
493.90  ASTHMA UNSPECIFIED
493.91  ASTHMA UNSPECIFIED TYPE WITH STATUS ASTHMATICUS
493.92  ASTHMA UNSPECIFIED WITH (ACUTE) EXACERBATION
691.8   OTHER ATOPIC DERMATITIS AND RELATED CONDITIONS
708.0   ALLERGIC URTICARIA
708.8   OTHER SPECIFIED URTICARIA
708.9   UNSPECIFIED URTICARIA
786.07  WHEEZING
989.5*  TOXIC EFFECT OF VENOM
995.0   OTHER ANAPHYLACTIC REACTION
995.1   ANGIONEUROTIC EDEMA NOT ELSEWHERE CLASSIFIED
995.20  UNSPECIFIED ADVERSE EFFECT OF UNSPECIFIED DRUG, MEDICINAL AND BIOLOGICAL SUBSTANCE
995.22  UNSPECIFIED ADVERSE EFFECT OF ANESTHESIA
995.27  OTHER DRUG ALLERGY
995.29  UNSPECIFIED ADVERSE EFFECT OF OTHER DRUG, MEDICINAL AND BIOLOGICAL SUBSTANCE
995.3   ALLERGY UNSPECIFIED NOT ELSEWHERE CLASSIFIED
995.60  ANAPHYLACTIC REACTION DUE TO UNSPECIFIED FOOD
995.61  ANAPHYLACTIC REACTION DUE TO PEANUTS
995.62  ANAPHYLACTIC REACTION DUE TO CRUSTACEANS
The term heavy metal testing is historically used to describe elements such as lead, arsenic, mercury, cadmium, and chromium. In general, all of the heavy metals in inorganic form cause GI irritation, resulting in nausea, vomiting, abdominal pain and diarrhea. The next most consistent toxicity for the heavy metals as a group, but not for every heavy metal, is renal toxicity. A further generalization is that each member of the heavy metal group tends to cause multi-organ toxicity. Many metals cause cutaneous abnormalities, such as irritant and allergic contact dermatitis, urticaria, keratoses, and premalignant and malignant lesions. Several of the heavy metals produce central and peripheral nervous system toxicity. Other metals cause pulmonary illness.

However, before any testing for heavy metal is ordered, a detailed medical history of the patient must be obtained, including a careful documentation of occupational and avocational exposure to these toxins. A complete physical examination must be done.

1. Aluminum. Serum aluminum testing is payable for beneficiaries who have been on dialysis with evidence suggesting aluminum toxicity, or for beneficiaries with chronic industrial exposure history.

2. Antimony. Serum and/or urine antimony testing is payable for beneficiaries with documented treatment in the past with antileishmaniasis agents or with documented chronic antimony industrial exposure history.

3. Arsenic. Serum and whole blood and/or urine arsenic testing is payable for beneficiaries with unexplained peripheral neuropathies, industrial exposure to arsenic, histories of arsenic pesticide exposure, unexplained encephalopathies, unexplained weight loss, chronic glomerulonephritis, bone marrow hypoplasia, or melanosis of skin, unexplained chronic diarrhea, persistent abdominal pain, or nausea and vomiting.

4. Barium. Serum and/or urine barium testing is payable for beneficiaries with pulmonary disease with industrial exposure to barium or unexplained flaccid paralysis.

5. Beryllium. Serum and/or urine beryllium testing is payable for beneficiaries with pulmonary disease with industrial exposure to beryllium.

6. Bismuth. Serum and/or urine bismuth testing is payable for beneficiaries with bismuth lines on their gums, methemoglobinemia, unexplained pathological fractures, or a history of bismuth medicine abuse.

7. Cadmium. Serum and whole blood and/or urine cadmium testing is payable for beneficiaries with an exposure to cadmium with evidence of pulmonary disease or unexplained renal failure.

8. Chromium. Serum chromium testing is payable for beneficiaries with an industrial exposure to chromium with evidence of pulmonary disease.
9. Cobalt. Serum cobalt testing is payable for beneficiaries with an industrial exposure to cobalt with evidence of pulmonary disease.

10. Copper. Serum copper testing is payable for beneficiaries with an industrial exposure to copper with evidence of pulmonary disease, or for beneficiaries with Wilson's Disease, unexplained cardiomyopathy, unexplained renal failure, polycythemia, unexplained myelodysplastic syndrome or known ingestion of zinc.

11. Iron. See the Laboratory National Coverage Determinations (NCDs) Database.

12. Lead. Blood (serum and whole) and/or urine lead testing is covered if there is documented industrial exposure to lead, documented avocation exposure to lead, retained bullet fragments at or near joints, a blue gum line, a history of moonshine abuse, unexplained peripheral neuropathies, evidence of lead contaminated drinking water, paint stripping, lead lines on bones on radiographs, or basophilic stippling of red blood cells.

13. Lithium. Serum and/or urine lithium testing is covered for beneficiaries on lithium medications.

14. Manganese. Serum manganese testing is covered for beneficiaries with documented industrial exposure to manganese.

15. Mercury. Serum, whole blood, and/or urine mercury testing is covered for beneficiaries with documented industrial exposure to mercury, with a blue line in their mouth, those with a history of laxative abuse, with a history of pesticide exposure, mercury spillage with vacuuming of the liquid metal, unexplained renal failure, or a history of skin lightening treatments.

16. Molybdenum. Serum molybdenum testing is covered for beneficiaries with documented industrial exposure to molybdenum.

17. Nickel. Serum and/or urine nickel testing is covered for beneficiaries with documented industrial exposure to nickel, unexplained renal failure, unexplained pulmonary disease.

18. Selenium. Serum and/or urine selenium testing is covered for beneficiaries with documented industrial exposure to selenium or on chronic renal dialysis.

19. Thallium. Serum thallium testing is covered for beneficiaries with documented industrial exposure to thallium and unexplained ataxia.

20. Tin. Serum tin testing is covered for beneficiaries with documented industrial exposure to tin.

21. Titanium. Serum titanium testing is covered for beneficiaries with documented industrial exposure to titanium.

22. Zinc. Serum zinc and/or urine testing is covered for beneficiaries with documented industrial exposure to zinc, on chronic renal dialysis, with malabsorption syndromes, Crohn's disease, unexplained myelodysplastic syndrome or known ingestion of zinc.

Documented recent, long-term total parenteral nutrition (TPN) with clinical trace element deficiency evidence is acceptable medical indications for testing for copper, manganese, and zinc.

CPT/HCPCS Codes

80178       LITHIUM
ICD-9 Codes that Support Medical Necessity

**Aluminum** - Group 1: Codes

292.2 PATHOLOGICAL DRUG INTOXICATION
292.81 DRUG-INDUCED DELIRIUM
292.82 DRUG-INDUCED PERSISTING DEMENTIA
292.83 DRUG-INDUCED PERSISTING AMNESTIC DISORDER
292.84 DRUG-INDUCED MOOD DISORDER
292.89 OTHER SPECIFIED DRUG-INDUCED MENTAL DISORDERS
293.9 UNSPECIFIED TRANSIENT MENTAL DISORDER IN CONDITIONS CLASSIFIED ELSEWHERE
294.8 OTHER PERSISTENT MENTAL DISORDERS DUE TO CONDITIONS CLASSIFIED ELSEWHERE
585.1 - 585.6 CHRONIC KIDNEY DISEASE, STAGE I - END STAGE RENAL DISEASE
585.9 CHRONIC KIDNEY DISEASE, UNSPECIFIED
973.0 POISONING BY ANTACIDS AND ANTIGASTRIC SECRETION DRUGS
985.8 TOXIC EFFECT OF OTHER SPECIFIED METALS
996.73 OTHER COMPLICATIONS DUE TO RENAL DIALYSIS DEVICE IMPLANT AND GRAFT

**Antimony** - Group 2: Codes
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>085.9</td>
<td>LEISHMANIASIS UNSPECIFIED</td>
</tr>
<tr>
<td>985.4</td>
<td>TOXIC EFFECT OF ANTIMONY AND ITS COMPOUNDS</td>
</tr>
</tbody>
</table>

**Arsenic** - Group 3: Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>284.89</td>
<td>OTHER SPECIFIED APLASTIC ANEMIAS</td>
</tr>
<tr>
<td>348.30</td>
<td>ENCEPHALOPATHY UNSPECIFIED</td>
</tr>
<tr>
<td>348.31</td>
<td>METABOLIC ENCEPHALOPATHY</td>
</tr>
<tr>
<td>348.39</td>
<td>OTHER ENCEPHALOPATHY</td>
</tr>
<tr>
<td>356.0</td>
<td>HEREDITARY PERIPHERAL NEUROPATHY</td>
</tr>
<tr>
<td>356.9</td>
<td>UNSPECIFIED IDIOPATHIC PERIPHERAL NEUROPATHY</td>
</tr>
<tr>
<td>357.7</td>
<td>POLYNEUROPATHY DUE TO OTHER TOXIC AGENTS</td>
</tr>
<tr>
<td>569.89</td>
<td>OTHER SPECIFIED DISORDERS OF INTESTINES</td>
</tr>
<tr>
<td>582.9</td>
<td>CHRONIC GLOMERULONEPHRITIS WITH UNSPECIFIED PATHOLOGICAL LESION IN KIDNEY</td>
</tr>
<tr>
<td>692.4</td>
<td>CONTACT DERMATITIS AND OTHER ECZEMA DUE TO OTHER CHEMICAL PRODUCTS</td>
</tr>
<tr>
<td>783.21</td>
<td>LOSS OF WEIGHT</td>
</tr>
<tr>
<td>787.01</td>
<td>NAUSEA WITH VOMITING</td>
</tr>
<tr>
<td>787.91</td>
<td>DIARRHEA</td>
</tr>
<tr>
<td>961.1</td>
<td>POISONING BY ARSENICAL ANTI-INFECTIVES</td>
</tr>
<tr>
<td>985.1</td>
<td>TOXIC EFFECT OF ARSENIC AND ITS COMPOUNDS</td>
</tr>
</tbody>
</table>

**Barium** - Group 4: Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>518.89</td>
<td>OTHER DISEASES OF LUNG NOT ELSEWHERE CLASSIFIED</td>
</tr>
<tr>
<td>985.8</td>
<td>TOXIC EFFECT OF OTHER SPECIFIED METALS</td>
</tr>
</tbody>
</table>

**Beryllium** - Group 5: Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>518.89</td>
<td>OTHER DISEASES OF LUNG NOT ELSEWHERE CLASSIFIED</td>
</tr>
<tr>
<td>985.3</td>
<td>TOXIC EFFECT OF BERYLLIUM AND ITS COMPOUNDS</td>
</tr>
</tbody>
</table>

**Bismuth** - Group 6: Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>289.7</td>
<td>METHEMOGLOBINEMIA</td>
</tr>
<tr>
<td>523.8</td>
<td>OTHER SPECIFIED PERIODONTAL DISEASES</td>
</tr>
<tr>
<td>733.10</td>
<td>PATHOLOGICAL FRACTURE UNSPECIFIED SITE</td>
</tr>
<tr>
<td>985.8</td>
<td>TOXIC EFFECT OF OTHER SPECIFIED METALS</td>
</tr>
</tbody>
</table>

**Cadmium** - Group 7: Codes
518.89 OTHER DISEASES OF LUNG NOT ELSEWHERE CLASSIFIED
586 RENAL FAILURE UNSPECIFIED
985.5 TOXIC EFFECT OF CADMIUM AND ITS COMPOUNDS

Chromium - Group 8: Codes
518.89 OTHER DISEASES OF LUNG NOT ELSEWHERE CLASSIFIED
985.6 TOXIC EFFECT OF CHROMIUM

Cobalt - Group 9: Codes
518.89 OTHER DISEASES OF LUNG NOT ELSEWHERE CLASSIFIED
985.8 TOXIC EFFECT OF OTHER SPECIFIED METALS

Copper - Group 10: Codes
238.72 - LOW GRADE MYELODYSPLASTIC SYNDROME LESIONS - MYELODYSPLASTIC SYNDROME, UNSPECIFIED
238.75 DISORDERS OF COPPER METABOLISM
275.1 SECONDARY CARDIOMYOPATHY UNSPECIFIED
425.9 SECONDARY CARDIOMYOPATHY UNSPECIFIED
518.89 OTHER DISEASES OF LUNG NOT ELSEWHERE CLASSIFIED
571.40 CHRONIC HEPATITIS UNSPECIFIED
571.41 CHRONIC PERSISTENT HEPATITIS
571.5 CIRRHOSIS OF LIVER WITHOUT ALCOHOL
571.9 UNSPECIFIED CHRONIC LIVER DISEASE WITHOUT ALCOHOL
573.9 UNSPECIFIED DISORDER OF LIVER
586 RENAL FAILURE UNSPECIFIED
759.89 OTHER SPECIFIED CONGENITAL ANOMALIES
783.3 FEEDING DIFFICULTIES AND MISMANAGEMENT
790.5 OTHER NONSPECIFIC ABNORMAL SERUM ENZYME LEVELS
985.8 TOXIC EFFECT OF OTHER SPECIFIED METALS

Iron - See Laboratory National Coverage Determinations (NCDs) Database - Group 11: Codes
XX000 Not Applicable

Lead - Group 12: Codes
348.30 ENCEPHALOPATHY UNSPECIFIED
348.31 METABOLIC ENCEPHALOPATHY
348.39 OTHER ENCEPHALOPATHY
354.8 OTHER MONONEURITIS OF UPPER LIMB
354.9 MONONEURITIS OF UPPER LIMB UNSPECIFIED
355.8 MONONEURITIS OF LOWER LIMB UNSPECIFIED
355.9 MONONEURITIS OF UNSPECIFIED SITE
356.0 HEREDITARY PERIPHERAL NEUROPATHY
356.1 PERONEAL MUSCULAR ATROPHY
356.2 HEREDITARY SENSORY NEUROPATHY
356.3 REFSUM'S DISEASE
356.4 IDIOPATHIC PROGRESSIVE POLYNEUROPATHY
356.8 OTHER SPECIFIED IDIOPATHIC PERIPHERAL NEUROPATHY
356.9 UNSPECIFIED IDIOPATHIC PERIPHERAL NEUROPATHY
790.01 PRECIPITOUS DROP IN HEMATOCRIT
790.09 OTHER ABNORMALITY OF RED BLOOD CELLS
793.7 NONSPECIFIC (ABNORMAL) FINDINGS ON RADIOLOGICAL AND OTHER EXAMINATION OF MUSCULOSKELETAL SYSTEM
984.0 TOXIC EFFECT OF INORGANIC LEAD COMPOUNDS
984.1 TOXIC EFFECT OF ORGANIC LEAD COMPOUNDS
984.8 TOXIC EFFECT OF OTHER LEAD COMPOUNDS
984.9 TOXIC EFFECT OF UNSPECIFIED LEAD COMPOUND

**Lithium** - Group 13: Codes

296.00 BIPOLAR I DISORDER, SINGLE MANIC EPISODE, UNSPECIFIED
296.01 BIPOLAR I DISORDER, SINGLE MANIC EPISODE, MILD
296.02 BIPOLAR I DISORDER, SINGLE MANIC EPISODE, MODERATE
296.03 BIPOLAR I DISORDER, SINGLE MANIC EPISODE, SEVERE, WITHOUT MENTION OF PSYCHOTIC BEHAVIOR
296.04 BIPOLAR I DISORDER, SINGLE MANIC EPISODE, SEVERE, SPECIFIED AS WITH PSYCHOTIC BEHAVIOR
296.05 BIPOLAR I DISORDER, SINGLE MANIC EPISODE, IN PARTIAL OR UNSPECIFIED REMISSION
296.06 BIPOLAR I DISORDER, SINGLE MANIC EPISODE, IN FULL REMISSION
296.10 MANIC AFFECTION DISORDER RECURRENT EPISODE UNSPECIFIED DEGREE
296.11 MANIC AFFECTION DISORDER RECURRENT EPISODE MILD DEGREE
296.12 MANIC AFFECTION DISORDER RECURRENT EPISODE MODERATE DEGREE
296.13 MANIC AFFECTION DISORDER RECURRENT EPISODE SEVERE DEGREE WITHOUT PSYCHOTIC
BEHAVIOR

296.14 MANIC AFFECTIVE DISORDER RECURRENT EPISODE SEVERE DEGREE SPECIFIED AS WITH PSYCHOTIC BEHAVIOR
296.15 MANIC AFFECTIVE DISORDER RECURRENT EPISODE IN PARTIAL OR UNSPECIFIED REMISSION
296.16 MANIC AFFECTIVE DISORDER RECURRENT EPISODE IN FULL REMISSION
296.20 MAJOR DEPRESSIVE AFFECTIVE DISORDER SINGLE EPISODE UNSPECIFIED DEGREE
296.21 MAJOR DEPRESSIVE AFFECTIVE DISORDER SINGLE EPISODE MILD DEGREE
296.22 MAJOR DEPRESSIVE AFFECTIVE DISORDER SINGLE EPISODE MODERATE DEGREE
296.23 MAJOR DEPRESSIVE AFFECTIVE DISORDER SINGLE EPISODE SEVERE DEGREE WITHOUT PSYCHOTIC BEHAVIOR
296.24 MAJOR DEPRESSIVE AFFECTIVE DISORDER SINGLE EPISODE SEVERE DEGREE SPECIFIED AS WITH PSYCHOTIC BEHAVIOR
296.25 MAJOR DEPRESSIVE AFFECTIVE DISORDER SINGLE EPISODE IN PARTIAL OR UNSPECIFIED REMISSION
296.26 MAJOR DEPRESSIVE AFFECTIVE DISORDER SINGLE EPISODE IN FULL REMISSION
296.30 MAJOR DEPRESSIVE AFFECTIVE DISORDER RECURRENT EPISODE UNSPECIFIED DEGREE
296.31 MAJOR DEPRESSIVE AFFECTIVE DISORDER RECURRENT EPISODE MILD DEGREE
296.32 MAJOR DEPRESSIVE AFFECTIVE DISORDER RECURRENT EPISODE MODERATE DEGREE
296.33 MAJOR DEPRESSIVE AFFECTIVE DISORDER RECURRENT EPISODE SEVERE DEGREE WITHOUT PSYCHOTIC BEHAVIOR
296.34 MAJOR DEPRESSIVE AFFECTIVE DISORDER RECURRENT EPISODE SEVERE DEGREE SPECIFIED AS WITH PSYCHOTIC BEHAVIOR
296.35 MAJOR DEPRESSIVE AFFECTIVE DISORDER RECURRENT EPISODE IN PARTIAL OR UNSPECIFIED REMISSION
296.36 MAJOR DEPRESSIVE AFFECTIVE DISORDER RECURRENT EPISODE IN FULL REMISSION
296.40 BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MANIC, UNSPECIFIED
296.41 BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MANIC, MILD
296.42 BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MANIC, MODERATE
296.43 BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MANIC, SEVERE, WITHOUT MENTION OF PSYCHOTIC BEHAVIOR
296.44 BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MANIC, SEVERE, SPECIFIED AS WITH PSYCHOTIC BEHAVIOR
296.45 BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MANIC, IN PARTIAL OR UNSPECIFIED REMISSION
296.46 BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MANIC, IN FULL REMISSION
296.50 BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) DEPRESSED, UNSPECIFIED
296.51  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) DEPRESSED, MILD
296.52  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) DEPRESSED, MODERATE
296.53  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) DEPRESSED, SEVERE, WITHOUT MENTION OF PSYCHOTIC BEHAVIOR
296.54  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) DEPRESSED, SEVERE, SPECIFIED AS WITH PSYCHOTIC BEHAVIOR
296.55  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) DEPRESSED, IN PARTIAL OR UNSPECIFIED REMISSION
296.56  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) DEPRESSED, IN FULL REMISSION
296.60  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MIXED, UNSPECIFIED
296.61  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MIXED, MILD
296.62  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MIXED, MODERATE
296.63  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MIXED, SEVERE, WITHOUT MENTION OF PSYCHOTIC BEHAVIOR
296.64  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MIXED, SEVERE, SPECIFIED AS WITH PSYCHOTIC BEHAVIOR
296.65  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MIXED, IN PARTIAL OR UNSPECIFIED REMISSION
296.66  BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) MIXED, IN FULL REMISSION
296.7   BIPOLAR I DISORDER, MOST RECENT EPISODE (OR CURRENT) UNSPECIFIED
296.80  BIPOLAR DISORDER, UNSPECIFIED
296.81  ATYPICAL MANIC DISORDER
296.82  ATYPICAL DEPRESSIVE DISORDER
296.89  OTHER AND UNSPECIFIED BIPOLAR DISORDERS, OTHER
296.90  UNSPECIFIED EPISODIC MOOD DISORDER
296.99  OTHER SPECIFIED EPISODIC MOOD DISORDER
311   DEPRESSIVE DISORDER NOT ELSEWHERE CLASSIFIED
969.8  POISONING BY OTHER SPECIFIED PSYCHOTROPIC AGENTS
985.8  TOXIC EFFECT OF OTHER SPECIFIED METALS
V58.63  LONG-TERM (CURRENT) USE OF ANTIPLATELETS/ANTITHROMBOTICS
V58.64  LONG-TERM (CURRENT) USE OF NONSTEROIDAL ANTI-INFLAMMATORIES
V58.65  LONG-TERM (CURRENT) USE OF STEROIDS
V58.69  LONG-TERM (CURRENT) USE OF OTHER MEDICATIONS
V58.83  ENCOUNTER FOR THERAPEUTIC DRUG MONITORING
Manganese - Group 14: Codes
333.90 UNSPECIFIED EXTRAPYRAMIDAL DISEASE AND ABNORMAL MOVEMENT DISORDER
333.99 OTHER EXTRAPYRAMIDAL DISEASES AND ABNORMAL MOVEMENT DISORDERS
783.3 FEEDING DIFFICULTIES AND MISMANAGEMENT
985.2 TOXIC EFFECT OF MANGANESE AND ITS COMPOUNDS

Mercury - Group 15: Codes
333.90 UNSPECIFIED EXTRAPYRAMIDAL DISEASE AND ABNORMAL MOVEMENT DISORDER
333.99 OTHER EXTRAPYRAMIDAL DISEASES AND ABNORMAL MOVEMENT DISORDERS
334.0 FRIEDREICH'S ATAXIA
334.3 OTHER CEREBELLAR ATAXIA
334.4 CEREBELLAR ATAXIA IN DISEASES CLASSIFIED ELSEWHERE
438.84 ATAXIA
586 RENAL FAILURE UNSPECIFIED
781.3 LACK OF COORDINATION
961.2 POISONING BY HEAVY METAL ANTI-INFECTIVES
973.3 POISONING BY OTHER CATHARTICS INCLUDING INTESTINAL ATONIA
976.8 POISONING BY OTHER AGENTS PRIMARILY AFFECTING SKIN AND MUCOUS MEMBRANE
985.0 TOXIC EFFECT OF MERCURY AND ITS COMPOUNDS

Molybdenum - Group 16: Codes
985.8 TOXIC EFFECT OF OTHER SPECIFIED METALS

Nickel - Group 17: Codes
518.89 OTHER DISEASES OF LUNG NOT ELSEWHERE CLASSIFIED
586 RENAL FAILURE UNSPECIFIED
985.8 TOXIC EFFECT OF OTHER SPECIFIED METALS

Selenium - Group 18: Codes
586 RENAL FAILURE UNSPECIFIED
985.8 TOXIC EFFECT OF OTHER SPECIFIED METALS

Thallium - Group 19: Codes
357.7 POLYNEUROPATHY DUE TO OTHER TOXIC AGENTS
781.3 LACK OF COORDINATION
985.8 TOXIC EFFECT OF OTHER SPECIFIED METALS

Tin - Group 20: Codes
985.8 TOXIC EFFECT OF OTHER SPECIFIED METALS

Titanium - Group 21: Codes
985.8 TOXIC EFFECT OF OTHER SPECIFIED METALS

Zinc - Group 22: Codes
238.72 - LOW GRADE MYELODYSPLASTIC SYNDROME LESIONS - MYELODYSPLASTIC SYNDROME,
238.75 - UNSPECIFIED
555.9 - REGIONAL ENTERITIS OF UNSPECIFIED SITE
579.9 - UNSPECIFIED INTESTINAL MALABSORPTION
586 - RENAL FAILURE UNSPECIFIED
783.3 - FEEDING DIFFICULTIES AND MISMANAGEMENT
985.8 TOXIC EFFECT OF OTHER SPECIFIED METALS

Group 23: Codes
Boron - No covered ICD-9 codes
Phosphorous - No covered ICD-9 codes
Silica - No covered ICD-9 codes
Strontium - No covered ICD-9 codes
Sulfur - No covered ICD-9 codes
Uranium - No covered ICD-9 codes
Vanadium - No covered ICD-9 codes